STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma
Clinically meaningful improvements were observed; eflornithine + lomustine doubled PFS and improved OS in patients with recurrent <i>IDH</i>-mutant, grade 3 astrocytoma, but not grade 4 tumors, after prior radiotherapy and TMZ, consistent with its cytostatic mechanism of action.
Authors
- Annick Desjardins (ORCID: https://orcid.org/0000-0003-3869-8283)
- Warren Mason (ORCID: https://orcid.org/0000-0001-9107-2242)
- Patrick Yung Wen (ORCID: https://orcid.org/0000-0002-0774-7700)
- Roy E. Strowd (ORCID: https://orcid.org/0000-0001-6651-5267)
- Tobias Walbert (ORCID: https://orcid.org/0000-0003-0667-8106)
- Sani H. Kizilbash (ORCID: https://orcid.org/0000-0001-8568-1519)
- Marshall Pitz (ORCID: https://orcid.org/0000-0002-1858-5081)
- Peter Hau (ORCID: https://orcid.org/0000-0003-3894-5053)
- Howard Colman (ORCID: https://orcid.org/0000-0002-4027-7317)
- Eric T. Wong (ORCID: https://orcid.org/0000-0001-7112-6207)
- Jörg Dietrich (ORCID: https://orcid.org/0000-0001-8291-0136)
- Liam Welsh (ORCID: https://orcid.org/0000-0001-9150-0737)
- Erik J. Uhlmann (ORCID: https://orcid.org/0000-0003-1432-4754)
- Andrew B. Lassman (ORCID: https://orcid.org/0000-0001-7386-9928)
- Marica Eoli (ORCID: https://orcid.org/0000-0003-4744-9377)
- Giuseppe Lombardi (ORCID: https://orcid.org/0000-0003-1316-2132)
- David Piccioni (ORCID: https://orcid.org/0000-0001-6006-0126)
- David M. Peereboom (ORCID: https://orcid.org/0000-0001-7798-5176)
- Burt Nabors (ORCID: https://orcid.org/0000-0001-5926-2230)
- Carlos Kamiya Matsuoka (ORCID: https://orcid.org/0000-0003-3216-2728)
- Alessia Pellerino (ORCID: https://orcid.org/0000-0003-3243-0059)
- Enrico C. Lallana
- Peter Forsyth (ORCID: https://orcid.org/0000-0002-3756-8594)
- Riccardo Soffietti (ORCID: https://orcid.org/0000-0002-9204-7038)
- Nicholas Butowski (ORCID: https://orcid.org/0000-0001-5162-2406)
- Priya Kumthekar (ORCID: https://orcid.org/0000-0001-5923-0677)
- Chao Wang (ORCID: https://orcid.org/0000-0001-8126-8970)
- Mohamed A. Hamza (ORCID: https://orcid.org/0009-0006-1607-9288)
- Victor A. Levin (ORCID: https://orcid.org/0000-0003-3909-2101)
Institutions
- OhioHealth (US)
- Beth Israel Deaconess Medical Center (US)
- Cleveland Clinic (US)
- Royal Marsden NHS Foundation Trust (GB)
- NewYork–Presbyterian Hospital (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- University of California, San Francisco (US)
- Wayne State University (US)
- Brown University (US)
- UC San Diego Health System (US)
- Huntsman Cancer Institute (US)
- Princess Margaret Cancer Centre (CA)
- Moffitt Cancer Center (US)
- University Hospital Regensburg (DE)
- University of Alabama at Birmingham (US)
- University of California San Diego (US)
- Massachusetts General Hospital (US)
- CancerCare Manitoba (CA)
- Istituto Oncologico Veneto (IT)
- Neuroscience Institute (IT)
- Dana-Farber Cancer Institute (US)
- Royal Marsden Hospital (GB)
- Kaiser Permanente Sacramento Medical Center (US)
- Mayo Clinic in Arizona (US)
- Candiolo Cancer Institute (IT)
- Pediatric Brain Tumor Foundation (US)
- Neurological Surgery (US)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Herbert Irving Comprehensive Cancer Center
- Wake Forest University (US)
- University of Turin (IT)
- Columbia University (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1200/jco-25-01204
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00